FMS-like tyrosine kinase 3 (FLT3) gene mutations were observed in approximately 30% of AML cases, including 25% internal tandem duplication (ITD) and 7–10% tyrosine kinase domain (TKD) mutation (Daver et al., 2019). This evidence concerns the gene FLT3 and acute myeloid leukemia.